Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2025 Financial Results on August 7, 2025
Organogenesis Holdings (Nasdaq: ORGO), a regenerative medicine company specializing in Advanced Wound Care and Surgical and Sports Medicine markets, has scheduled its second quarter fiscal year 2025 earnings release for August 7, 2025, after market close.
Management will host a conference call at 5:00 p.m. Eastern Time on the same day to discuss quarterly results and provide a corporate update. Investors can join via webcast or teleconference using the number 800-715-9871 (646-307-1963 for international) with access code 634899. The webcast will be available on the company's investor relations website for approximately one year.
Organogenesis Holdings (Nasdaq: ORGO), un'azienda di medicina rigenerativa specializzata nei mercati della Cura Avanzata delle Ferite e della Medicina Chirurgica e Sportiva, ha programmato la pubblicazione dei risultati del secondo trimestre dell'anno fiscale 2025 per il 7 agosto 2025, dopo la chiusura del mercato.
La direzione terrà una conference call alle 17:00 ora della costa orientale lo stesso giorno per discutere i risultati trimestrali e fornire un aggiornamento aziendale. Gli investitori potranno partecipare tramite webcast o teleconferenza chiamando il numero 800-715-9871 (646-307-1963 per l'internazionale) con codice di accesso 634899. Il webcast sarà disponibile sul sito web delle relazioni con gli investitori della società per circa un anno.
Organogenesis Holdings (Nasdaq: ORGO), una empresa de medicina regenerativa especializada en los mercados de Cuidado Avanzado de Heridas y Medicina Quirúrgica y Deportiva, ha programado la publicación de sus resultados del segundo trimestre del año fiscal 2025 para el 7 de agosto de 2025, después del cierre del mercado.
La dirección realizará una conferencia telefónica a las 5:00 p.m. hora del Este ese mismo día para discutir los resultados trimestrales y proporcionar una actualización corporativa. Los inversores pueden unirse a través de webcast o teleconferencia usando el número 800-715-9871 (646-307-1963 para llamadas internacionales) con código de acceso 634899. El webcast estará disponible en el sitio web de relaciones con inversores de la compañía durante aproximadamente un año.
Organogenesis Holdings (나스닥: ORGO)는 상처 치료 및 수술 및 스포츠 의학 시장을 전문으로 하는 재생 의학 회사로, 2025 회계연도 2분기 실적 발표를 2025년 8월 7일 시장 마감 후에 예정하고 있습니다.
경영진은 같은 날 동부 표준시 기준 오후 5시에 컨퍼런스 콜을 개최하여 분기 실적을 논의하고 회사 업데이트를 제공합니다. 투자자들은 웹캐스트 또는 전화 회의(국내: 800-715-9871, 국제: 646-307-1963) 접속 코드 634899를 통해 참여할 수 있습니다. 웹캐스트는 회사 투자자 관계 웹사이트에서 약 1년간 시청할 수 있습니다.
Organogenesis Holdings (Nasdaq : ORGO), une entreprise de médecine régénérative spécialisée dans les marchés des soins avancés des plaies ainsi que de la chirurgie et de la médecine sportive, a prévu la publication des résultats du deuxième trimestre de l'exercice 2025 pour le 7 août 2025, après la clôture du marché.
La direction animera une conférence téléphonique à 17h00 heure de l'Est le même jour pour discuter des résultats trimestriels et fournir une mise à jour de la société. Les investisseurs peuvent participer via webcast ou téléconférence en composant le 800-715-9871 (646-307-1963 pour l'international) avec le code d'accès 634899. Le webcast sera disponible sur le site des relations investisseurs de la société pendant environ un an.
Organogenesis Holdings (Nasdaq: ORGO), ein Unternehmen für regenerative Medizin, das sich auf die Märkte für fortschrittliche Wundversorgung sowie chirurgische und Sportmedizin spezialisiert hat, hat die Veröffentlichung der Ergebnisse für das zweite Quartal des Geschäftsjahres 2025 für den 7. August 2025 nach Börsenschluss geplant.
Das Management wird am selben Tag um 17:00 Uhr Eastern Time eine Telefonkonferenz abhalten, um die Quartalsergebnisse zu besprechen und ein Unternehmensupdate zu geben. Investoren können per Webcast oder Telefonkonferenz teilnehmen, indem sie die Nummer 800-715-9871 (für internationale Anrufe 646-307-1963) mit dem Zugangscode 634899 wählen. Der Webcast wird etwa ein Jahr lang auf der Investor-Relations-Website des Unternehmens verfügbar sein.
- None.
- None.
CANTON, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that second quarter of fiscal year 2025 financial results will be reported after the market closes on Thursday, August 7th.
Management will host a conference call at 5:00 p.m. Eastern Time on August 7th to discuss the results of the quarter, and to provide a corporate update with a question and answer session. Those who would like to participate may access the live webcast here, or access the teleconference by dialing 800-715-9871 (646-307-1963 for international callers) and providing access code: 634899. The live webcast can also be accessed via the company’s website at investors.organogenesis.com. The webcast will be archived on the company website for approximately one year.
About Organogenesis Holdings Inc.
Organogenesis Holdings Inc. is a leading regenerative medicine company focused on the development, manufacture, and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. Organogenesis offers a comprehensive portfolio of innovative regenerative products to address patient needs across the continuum of care. For more information, visit www.organogenesis.com.
Investor Inquiries: ICR Healthcare Mike Piccinino, CFA OrganoIR@icrinc.com Press and Media Inquiries: Organogenesis communications@organo.com
FAQ
When will Organogenesis Holdings (ORGO) report Q2 2025 earnings?
What time is the Organogenesis Holdings Q2 2025 earnings call?
How can I access the Organogenesis Holdings Q2 2025 earnings call?
How long will the Organogenesis Holdings Q2 2025 earnings webcast be available?
